Advancing Therapeutic IgE – Collaborative Discovery of MOv18's Mechanism in Ovarian Cancer
April 10, 2025
Summary: Ovarian cancer is the most lethal gynecological malignancy, with limited treatment options and a profoundly immunosuppressive tumor microenvironment (TME). Tumor-associated macrophages
(TAMs) are abundant in ovarian tumors and ascites, where they play a major role in suppressing
anti-tumor T cell responses.
In this collaborative study with King’s College London, researchers explored a first-in-class IgE
monoclonal antibody (mAb), MOv18 IgE, targeting Folate Receptor- (FR ), and investigated how it
reshapes macrophage behavior and T cell interactions, using Seromyx's profiling tools to uncover
previously uncharacterized Fc effector mechanisms.
Antibody Engineering & Therapeutics 2025
The World Vaccine Congress Europe 2025
Festival of Biologics
The Fc-Mediated Effector Function Summit
Authors: Kaplonek P, et al. Sci Transl Med. 2022 May 18;14(645):eabm2311.
Authors: Hawman, David W. et al. eBioMedicine, Volume 115, 105698
Authors: Crescioli, S, Jatiani, S, & Moise, L, (2025). mAbs, 17(1). Journal: mAbs
Authors: Osborn, G., López-Abente, J., Adams, R. et al.
Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...
Authors: P. Hsueh, M. Friedman, S. Jatiani (2024) Application Note
